Med Life SA

Med Life SA

BBVB:M
9.56
RON
-0.20
(-2.05%)
-0.10EPS
6.30BMarket Cap
Nov 23Next Earn

Q3 FY2026 · Earnings Call TranscriptNovember 20, 2026

Operator

Ladies and gentlemen, thank you for standing by. I'm Vasilios, your Chorus Call operator.

Welcome, and thank you for joining the MedLife conference call to present and discuss the nine-month 2026 financial results. Please note that the conference call is being recorded, and during the management's presentation, all participants will be in a listen-only mode.

The presentation will be followed by a question-and-answer session, and you can submit questions via the webcast platform or via telephone. Should anyone need assistance during the conference call, you may signal an operator by pressing star and zero on your telephone or by dialling the phone numbers under the ask a question section on the webcast page.

At this time, I would like to turn the conference over to Mr. Mihail Marcu, CEO and Chairman of the Board.

Mr. Marcu, you may now proceed.

Mihail Marcu

Thank you. Good evening, everybody.

Thank you so for joining our conference today. Today we are here with Mr.

Dorin Preda, the Deputy CEO, with Flavia Cimpean, she is the Corporate Finance and Sustainability, and of course our IR manager, Ioana Bîrsu. I will let now the phone to Flavia.

She's going to make the main presentation. Of course, after that we will be here for your Q&A session.

Flavia, please take over.

Flavia Cimpean

Yes, thank you. Good afternoon, everyone, and thank you for joining our presentation today.

We will start this presentation with the highlights for the first nine months of this year. We continue to deliver solid business growth, with pro forma consolidated revenue increasing by 12% year-on-year to 2.6 billion RON.

Importantly, 11.2% of this growth was organic, reflecting sustained patient activity and continued demand for private healthcare services. We also saw clear improvement in profitability, with the pro forma EBITDA margin reaching 16.7% for the nine-month period.

This reflects the stronger operating performance recorded in Q2 and Q3. Another important aspect is that the benefits and operating leverage are becoming increasingly visible.

As our business grows, we are seeing better absorption of fixed costs. Together with our continued focus on efficiency, cost discipline, and operational optimization, this has supported margin expansion and helps us navigate the ongoing inflationary environment.

Growth remained broad-based across the group's business lines, demonstrating the resilience of our diversified platform. This is particularly relevant in the current environment where consumer spending remains cautious, yet demand for healthcare services continues to be relatively resilient.

At the same time, we continue to advance our strategic development agenda, with investments focused on expanding our infrastructure, strengthening our high-end medical capabilities, developing personalized healthcare solutions, and accelerating our digital and technology initiatives. Overall, we enter the final quarter of the year with positive operating momentum, supported by consistent revenue growth, improving profitability, and continued progress across our strategic priorities.

Moving on to the M&A and organic growth, I would like to highlight two important developments from the third quarter. First, in August, we announced the acquisition of a 75% stake in Qualipath, a Romanian company specialized in anatomical pathology and molecular testing, with operations in Timișoara and Oradea and a nationwide coverage.

This transaction is strategically important as it strengthens our advanced diagnostics capabilities and complements our existing expertise in personalized medicine, particularly in a high-growth segment. Qualipath will continue to operate under its own brand and management team, ensuring business continuity while benefiting in parallel from the broader MedLife platform.

The closing is expected by the end of this year. The second major development was the launch of LEVEL UP by MedLife in August, marking the rebranding of our former Sweat fitness network.

This represents another step in our ambition to expand beyond traditional healthcare services and build a more integrated health, wellness, and prevention platform. Following an investment of approximately €0.5 million in the new Bucharest location, the network now comprises six clubs serving around 6,000 active members.

We plan to open four additional locations by early 2027 and have a target of 20 clubs by end of next year. We see LEVEL UP as an important component of our broader strategy to develop an integrated health and longevity ecosystem, connecting medical services with fitness, wellness, and prevention.

Turning now briefly to our organic expansion, we opened the MedLife Fundeni hyperclinic in Bucharest following an investment of more than €1 million. The new facility consolidates the former Fundeni clinic into a larger, integrated medical hub.

In Arad, MedLife Genesys also continued its expansion, opening its sports medical unit. The new location adds capacity across more than 17 medical specialties and laboratory diagnostics while introducing a longevity center concept focused on prevention and integrated health.

Finally, following the completion of the Medstar acquisition in January, the integration into the Sfânta Maria network started in February, further strengthening our presence in Cluj-Napoca and the wider Transylvania region. Overall, these developments illustrate how we are combining selective acquisitions with organic investments to expand our capabilities, strengthen our regional presence, and gradually build a more comprehensive healthcare and wellness ecosystem.

Beyond our continued expansion through acquisition and organic growth, we are also making progress on several strategic initiatives aimed at strengthening our digital capabilities and further differentiating our service offering. A major step in our digital transformation journey was the official launch of IMed, our new digital platform integrated into the MedLife app, which will also play an important role in our growth strategy for 2027.

The platform brings together a wide range of health-related information, including patients' medical history, laboratory results, genetic profiles, biometric data, and lifestyle information, all into a single, integrated ecosystem. Our ambition is to provide users with a more comprehensive picture of their health, helping them better understand their individual health profiles and take a more proactive approach to prevention and personalized care.

In addition, IMed includes educational content designed to support health awareness and encourage more informed decisions. We are already seeing encouraging developments in terms of user engagement with the MedLife app.

Organic downloads have increased by 40% year-on-year during May to October, twice the growth rate reported in the same period last year. Building on this momentum and the new functionalities, we plan to roll out by year-end.

Our objective is to double the number of app accounts by mid-2027. In fact, over the coming months, we aim to attract a number of new users comparable to the total number of accounts accumulated since the app first launched.

We believe that IMed will play an important role in accelerating adoption and encouraging users to engage with the platform more regularly. Moving on to Longevity 100+, we continue to expand the scope of this program, taking personalized medicine beyond genetic testing and traditional clinical data towards a more comprehensive understanding of individual health profiles.

Following the introduction of microbiome testing, which is performed entirely in our own laboratory in Romania, the next step will be the development of pharmacogenetics capabilities. This will allow us to better understand how individual genetic profiles influence patients' responses to different treatments, supporting more personalized therapeutic approaches.

At the same time, we are looking at how data collected through wearable devices can complement genetic information and provide additional insights into individual health patterns. This includes indicators such as resting heart rate, heart rate variability, physical activity, and sleep patterns, which we aim to correlate with genetic predisposition.

Overall, both IMed and Longevity 100+ reflect our ambition to move towards a more integrated and personalized healthcare model, combining medical expertise, technology, and data to support prevention and better patient outcomes. Now looking ahead, our priorities will remain centered on sustainable growth, innovation, and strengthening MedLife's competitive position while continuing to develop an integrated healthcare ecosystem.

An important part of this strategy will be to further leverage the investments we have made in digitalization and personalized medicine. In particular, we see significant potential in using IMed and the Longevity 100+ program to strengthen patient engagement, support prevention-oriented healthcare, and develop new ways of interacting with patients throughout their healthcare journey.

Our ambition is to increasingly integrate these capabilities into the group's business model, creating additional value for patients while supporting long-term growth and differentiation. On the development side, we remain focused on sustainable growth and disciplined capital allocation, combining organic expansion with selective M&A.

In Romania, we continue to see opportunities for small and medium-sized acquisitions, particularly across healthcare, beauty, and wellness sectors, where we can strengthen our existing footprint, expand our service portfolio, and capture operational synergies. At the same time, we are looking beyond our domestic market, exploring opportunities to extend our presence across the region, as we see this as a natural step in MedLife's development.

Over the past decades, we have built a strong track record in Romania and gained valuable experience in Hungary and the Republic of Moldova. We believe that the expertise accumulated in developing and integrating healthcare businesses across these markets can be leveraged in other countries in Central and Southeastern Europe, particularly in the Balkans.

To support these ambitions, we are working on the development of a regional investment platform alongside a leading international financial institution. The idea is to combine MedLife's operational expertise and in-depth understanding of the healthcare sector with our partner's financial resources and international investment expertise.

This would allow us to share investment risks and strengthen our capacity to pursue attractive opportunities across the region. The platform is expected to target companies in operating healthcare, prevention, and wellness, with investments gradually being deployed over a three to five-year period.

Depending on the specific market and opportunities available, we are considering different development models, including acquisitions, greenfield investments, and partnerships. We are currently working on developing this initiative, and we estimate that the first investments could start in the first half of 2027.

Importantly, our approach will remain disciplined. We are not looking at geographical expansion for its own sake, but rather at opportunities where we can leverage our operational experience, carefully assessing market potential, regulatory frameworks, the quality of potential partners, and expected returns.

Another important priority is to further diversify the group's financial instruments and ensure the financial flexibility needed to support our next stage of development. Over the years, MedLife has grown through a combination of organic expansion, acquisitions, and investments in medical infrastructure and technology.

As we move into the next phase, we believe it is important to have additional financing alternatives and not rely exclusively on debt to fund our growth. In this context, our shareholders approved earlier this week an authorization allowing the Board of Directors to increase the share capital by up to 20% of the current subscribed capital over an 18-month period.

It is important to highlight that this represents the maximum capacity authorized by shareholders rather than a predetermined target or a commitment to issue the full amount. A potential capital increase would provide additional flexibility to support several strategic priorities, including organic expansion, investments in medical infrastructure and equipment, technology and innovation, as well as selective M&A opportunities and further consolidation of the markets in which we operate.

The authorization gives the board the flexibility to determine the timing, size, and structure of any potential transaction, taking into account market conditions and the investment opportunities available. Our intention is to maintain a disciplined approach to capital allocation, ensuring that any funds raised are directed towards opportunities capable of generating attractive long-term returns for shareholders while also supporting a sustainable financial structure.

It is also worth clarifying that the potential capital increase and the regional investment platform are two separate initiatives within our broader growth strategy. While the capital increase would provide MedLife with an additional financial flexibility to fund its development, the regional platform is being explored together with an international financial institution as a dedicated vehicle for pursuing investment opportunities across the region.

Moving on to the next section, the financial results and looking at the consolidated financial statement of profit and loss, we can look now at the nine-month 2026 pro forma versus nine-month 2025 IFRS, and we can see gross sales increased by 11.8%, reaching 2.6 billion RON. Gross sales are including the National Health Program for chemotherapy drugs.

The pro forma operating profit increased by 33.1%, reaching 163 million RON. The pro forma EBITDA increased by 17.8% to 398.7 million RON, resulting in a margin of 16.7% on a pro forma basis, with 14.6% on an IFRS basis adjusted for the one-off litigation expense registered in Q2, and compared with 14.3% in the first nine months of 2025.

The pro forma net result was a loss of 7.1 million RON, determined mainly by the approximately 2.8% depreciation of the RON against the euro during the second quarter. On our financial impact, particularly the unrealized FX loss, we are already taking steps to gradually reduce the group's exposure to euro-RON fluctuations and improve the currency balance of our financing structure.

As part of this process, in Q4 2026, we have already converted a portion of our existing loan financing into RON, reducing our exposure to foreign exchange risk. Furthermore, the conversion of an additional tranche is currently underway as we continue to gradually rebalance our debt structure.

Going forward, we will also consider local currency financing for new investments where appropriate to better align our funding structure with the currency in which we generate most of our revenue and cash flows. Another mitigating factor is the continued expansion of our corporate segment, which is a euro-denominated component of the group revenue.

As this business grows, it provides a natural hedge against part of the group's currency exposure. Together, these two risk-mitigating measures are expected to cover between a third and half of our FX exposure.

Ultimately, our aim is to progressively strengthen the alignment between our funding and cash flow currency while reducing the sensitivity of our financial results to exchange rate movements. Moving next to the next slide, in terms of the bridge in revenue from IFRS figures to pro forma figures, we have included 3 million RON normalization adjustments from subsidiaries integrated in the first nine months of the year, namely Medstar, that entered in the consolidation in February 2026.

We have also extracted 260.6 million RON reclassification of the National Health Program for chemotherapy drug in all our units, with comparables of 200 million RON for the same period in the last year. I remind you that this is a business with zero direct margin contribution, but very important in supporting volume growth in complementary service areas, and was always approached as an adjustment in pro forma figures.

In terms of the bridge in EBITDA from IFRS figures to pro forma figures, 108,000 RON correspond to the normalization adjustments from acquisition, and 21 million are non-current and non-operational expenses. Looking at a quarter-on-quarter evolution, I would highlight the improvement in our profitability during 2026, with a positive trend gaining momentum from the second quarter onwards.

Our EBITDA margin increased compared to the corresponding periods in the last year, reflecting continued growth in patient volumes, a more favorable mix of high-complexity services, better operating leverage, and ongoing efficiency measures implemented across our network. On the revenue side, we continue to see steady quarter-on-quarter revenue growth, driven primarily by increasing patient volumes across our existing network, complemented by the additional contribution from recently opened units and businesses integrated into the group.

Turning to the performance of each of our business lines, we continue to see solid growth across our core segments, with corporate, clinics, laboratories, and hospitals all contributing positively to the group's performance. Corporate remained one of the strongest performing segments, with revenues increasing by 21% year-on-year.

Growth continues to be supported by strong demand for corporate healthcare services, new client acquisition, and the expansion of existing contracts, confirming the resilience of this business line and its importance to the group. In clinics, revenues increased by 16% year-on-year, reflecting continued growth in patient volumes across our outpatient network.

We continue to benefit from the strength of our medical teams, the range of our service offering, and ongoing investments in expanding our capabilities. Hospitals also delivered solid results, with revenues growing by 10% compared to the same period last year.

Performance continues to be supported by patient demand and the increasing complexity of medical services provided across our hospital network. There are still certain hospital operations where profitability is below potential, mainly due to the time required to reach adequate patient volume and secure or expand contracts with the National Health Insurance House.

We see these as businesses with further development potential rather than structural profitability issues, and we believe that we will be able to enter into contracts with the National Health Insurance House in the short term. Laboratories recorded a 13% year-on-year increase in revenues, primarily driven by higher testing volumes.

The segment continues to benefit from sustained demand for diagnostic services as well as ongoing development of our advanced testing capabilities. Moving to pharmacies, revenues increased by 40% year-on-year.

This strong performance was driven by growth in both average sales per client and customer volumes, reflecting the continued development of this business line. Dentistry remained the segment facing the most challenging operating environment, with revenues declining by 1.4% year-on-year.

However, this represents a more moderate contraction compared to Q2 2026, suggesting some improvements in the trend. We have started implementing operational improvements and redefining the division's strategic positioning, with a stronger focus on medium to high-income customer segments.

Further initiatives are underway, and we expect their impact to materialize progressively over the coming period. Finally, others business line recorded a 40% decrease year-on-year, mainly reflecting lower activity in wholesale distribution.

Looking at the cost structure on the next slide, operating expenses as a percentage of sales improved slightly year-on-year, reflecting a combination of several factors. On one hand, consumables and repair materials accounted for a higher share of revenue, in line with the increasing contribution of oncology, laboratories, and hospital services to the group's revenue mix.

This was partly offset by the lower weight of commodities in total sales. On the other hand, personnel expenses as a percentage of revenue declined as business growth allowed us to achieve better absorption of our existing fixed-cost base.

This trend became more visible from the second quarter onwards, contributing positively to operating efficiency. Overall, these developments supported a gradual improvement of the operating cost ratio.

Turning now to the financial position on the next slide, non-current assets remained broadly stable, increasing by 1.7%. The main movement here was a 27 million RON increase in goodwill, following the acquisitions that were completed this year.

Current assets, excluding cash and cash equivalents, increased by 12%. This was partly in line with the growth in activity and partly related to the timing of advance payments and receivables.

As we discussed last quarters, receivables from the National Health Insurance House follow different payment and settlement patterns throughout the year compared with year-end, we can see some temporary fluctuations in the balance. This is primarily a timing effect.

On the other side of the balance sheet, current liabilities, excluding interest-bearing liabilities, increased by 13.5%, broadly reflecting the higher level of activity. Moving now to debt and leverage, financial debt increased by 7.7% during the period, resulting in a 6.4% increase in net debt.

The net debt to pro forma EBITDA stood at 3.67 at the end of September, reflecting a slight improvement compared to Q1 and H1, despite the approximately 3.5% depreciation of the RON against the euro in the first nine months of the year. If we were to exclude this currency effect, the current leverage ratio would have stood at around 3.54, indicating a more favorable underlying deleverage trend.

Looking ahead, we remain focused on disciplined capital allocation and improving our leverage position, with a short-term objective of gradually reducing net debt to pro forma EBITDA to less than 3.5 and more towards 3.1. Moving to the consolidated cash flow, we continue to see strong underlying cash generation during the first nine months of the year.

Operating cash flow before working capital increased by 10% year-on-year, reaching 375.5 million RON. Net cash generated from operating activities was 261.5 million RON, representing a 50% increase compared with the same period of 2025.

On the investment side, we allocated so far approximately 174 million RON to investing activities, mainly covering acquisitions and ongoing capital expenditure projects. Of this amount, 37 million RON was directed towards acquisition of subsidiaries, while 118 million RON was invested in property, plant, and equipment, supporting the continued development and modernization of our network and medical infrastructure.

This concludes our presentation for today, and we can now move to the Q&A session. We will take the first questions by phone, if any, and afterwards, we can move to the questions submitted through the platform.

Thank you, operator.

Operator

Thank you. Ladies and gentlemen, at this time, we will begin the question-and-answer session.

You can submit questions through the platform in the ask a question section or via telephone by dialling one of the numbers provided and pressing star followed by one on your telephone. If you wish to remove yourself from the question queue, then you may press star and two.

Please use your handset when asking your question for better quality. Anyone who has a question may press star and one at this time.

One moment for the first question, please. The first question comes from the line of Bram Buring with Wood & Co.

Please go ahead. ):

Bram Buring

Hello. Three, three questions, I think.

Firstly, you discussed agreement with the National Health House at the new hospitals. Did you say that you would expect to get an agreement with them in the fourth quarter, or did I hear badly?

Dorin Preda

The problem with the hospital will be solved, but unfortunately we cannot say that fourth quarter will be the time to solve that situation. Unfortunately we cannot come with this type of affirmation at the date.

):

Bram Buring

Understood. Second question would be with regards to the restructuring of the euro-denominated debt.

You said that one tranche has been refinanced as RON. Could you put a figure on exactly how much that was?

Flavia Cimpean

We already denominated €14 million, and we are now working on denominating another almost €16 million in the coming months.

Dorin Preda

Actually the idea, Bram, is that together with the new tranche and together with the natural hedge that the corporate division is providing to have almost half of the exposure to be protected, let me put it this

Bram Buring

way. ): If I understood correctly, you said you want to do this with was it one-third to one-half of your euro exposure?

Did I get the numbers right?

Mihail Marcu

Let me go in, Bram, for a moment. I will answer the both question a bit.

Number one, we are reducing the exposure towards euro gradually. We have done that, let's say, 5% to 7% from our exposure.

We intend to grow this and to add about 60 6-0 million in the first trimester of the 2027. We don't have a exactly plan for how is going to be and when is going to be half of this amount, but for the time being, we hope around €100 million will be done in the first half of the next year.

This is the number one. In respect with the two hospitals, what Flavia was trying to say, we are quite confident during next year, we will succeed to sign the contracts for the two hospitals.

Don't expect that all of a sudden will totally change this situation, because at the end of the day, these hospitals, they have 60 plus 100 hospitals each one. Now the National Health House allows you go first with 20 beds, then you go to 30 beds, then you go to 50 beds and so.

This situation is blocked for all the new hospitals in Romania, not for this particular two hospitals of MedLife. ): No,

Bram Buring

I remember that that is a thing. It's helpful,

Mihail Marcu

though. We are confident what we heard from the National Health House in the past two months.

It looks like we may be able during next year to do gradually some steps. We are confident during the 2027, at next year at this time, we are not going to be in the same situation with no contracts for these two hospitals.

):

Bram Buring

Understood. Thank you.

Then the final question is with regard to the regional investment platform that you mentioned. I believe that's the first time we're hearing about that.

Could you elaborate a little bit more? Who is the partner if you're able to disclose that?

What would the size of the platform be? How much would you have to spend on M&A through the platform with your partner?

Mihail Marcu

Thank you, Bram, for the question. Number one, we are discussing with one big IFI, with the one that we have a very long tradition and we know them for many years.

This is not have been disclosed. We did a press release about two weeks ago on this in respect with this move after our board, maybe one week ago, I don't remember exactly.

In our press release, we explain that expect to disburse €10 to €15 million per year in the next four years together with this fund, that may come with the same amount yearly. Why Flavia said this is a distinct operation than the capital increase?

Because number one, the capital increase will take over and we will use it as to develop our M&A activity and our natural growth in Romania especially. We would like, in case that we go with our expertise, with our know-how in the region, for example if we pass to Moldova to have a higher stake there, in Bulgaria or in Serbia, I'm just giving three examples, it doesn't mean this we commit to go to invest in these three countries, but this might be on the list.

Bram Buring

Then

Mihail Marcu

because of the governance of these countries and the way that these countries, they work with the private healthcare market there, we would like to be protected and go there with an IFI that can be a shield for us and in the same time to have local offices and expertise. Given the amount of 10 maybe €10 million, maybe €12 million per year in the coming four years, don't expect that is going to be used and crossed with the finance that we are obtaining now with in case that we do the increase of the capital.

It means that we can do from our cash flow Flavia just named the cash flow of MedLife, we are producing quite a good cash flow every year, close to €100 million per year, we can use our own funds to finance along with this IFI this investment outside Romania. Maybe in Romania, on wellness, maybe on dentistry, maybe on beauty, not necessary we are not using this platform to develop our healthcare sector in Romania.

I don't know if that answered your question. ):

Bram Buring

Out of this, you say €10 to €15 million annually, how much of your own funds would you be putting into the platform?

Mihail Marcu

Our own funds will be €10 million, and the other half is going to be this IFI, again in case that we realize this contract. We are not, let's say, not even halfway there.

Is our intention, we have some discussion, and we might finalize and start investing, I don't know, if everything goes well, next year we can do €10 to €15 million on this respect from our own pocket, from MedLife own funds, and another €10 to €15 million from the bank. Of course, I don't want to limit myself to this 10 to 15.

I'm trying to explain we want to invest together a max €100 million if this is going to happen in the coming four years, which is half from our pocket, half from their pocket, but we are not expecting to invest the full amount if this is going to be the amount. We are investing comparing with Romania where we are confident if we'll have an increase of capital of €100 million, we know how to do it.

We have done it in the past, and will not sit on this money maybe 18, 24 months, yes, of course, not in 5 months, but we know the Romanian market very well. Going abroad is a different animal, and we don't have the knowledge in this country, so that's why we need an IFI.

In case we'll succeed to sign such a contract, is going to be €15 million max per year or, I don't know, average €15 million, maximum €15 million average per year in the coming four years from our pocket. ):

Bram Buring

Understood. I'll step out of the queue.

Thank you very much.

Operator

The next question comes from the line of Laura Simion with Swiss Capital. Please go ahead.

Laura Simion

Good afternoon, and thank you for the presentation. I have a few questions also about regional expansion and then a couple of follow-up questions regarding the financial results.

Regarding the expansion in the region, how do you plan to adapt your business model given that indeed those country that you mentioned, Serbia, Bulgaria, the private medical services are generally provided through insurers and not like in Romania where you have direct contact with the companies? We are

Mihail Marcu

again, we are not even a 50% road with this discussion, I would prefer to stop here the discussion on this subject for the time being, of course not in the future. In case that we advance and we'll have something signed maybe in February or March, then of course we can elaborate on the topic.

Laura Simion

How will you see the margins there, because logically if you are working through insurers, the margins are lower, how do you plan to draw some synergies or something in order to not dilute the group margin, the group level?

Mihail Marcu

Sorry, if you can repeat the question. Is that related with going abroad?

Laura Simion

Yes, yes.

Mihail Marcu

What I'm saying is that we are not even at half road with this IFI discussion, I would prefer to elaborate and to discuss more on the topic in January, February if we go further with the IFI that we are discussing. Thank you.

Laura Simion

Okay. Now related to the financial results for Q3 and looking forward to Q4, do you expect in terms of clinic visits, hospital numbers of patients, and corporate subscriptions the same momentum like in Q3?

Or how do you compare for now the last quarter versus Q3?

Dorin Preda

I will take the question. The idea is that if you follow the results of all the year for all the quarters that have already passed, you will see that mainly of our growth is coming from having more patients than last year.

It looked for the beginning of the year that the average ticket is lower than one year before, but as you can see, as we go into the year, average ticket tends to stabilize and also have small increases. I would say that without having any intention to have forward-looking declaration here is that we expect that quarter four will have also a bigger number of patients than last year.

Laura Simion

In terms of margin, do you expect to keep the margin above 15% in Q4 like it was the case in Q3?

Dorin Preda

Actually we should look at seasonality. The fourth quarter, if you look also historically, tends to be a bit lower than third quarter.

I would not necessarily expect having the same margin of EBITDA in the fourth quarter, which is in line with our seasonality of results that you can see already in our history.

Mihail Marcu

Also I can add that we are keeping the budget expectations, you may simply calculate using that formula. We believe that the budget is achievable.

As you could see that our first two quarter were not so good as to show that the budget will be reached. We have been asked at the end of second quarter if we keep the budget given that we should have better margin in the second half in order to reach the budget, and we said yes, we trust that we can keep up with the budget.

The answer for the this year and the feeling is that we still keep the budget in mind as we proposed at the beginning of the year and approved by the shareholders.

Laura Simion

Thank you, that's all from my side.

Operator

As a reminder, if you would like to ask an audio question, please press star and one on your telephone. We have a follow-up question from the line of Bram Buring with Wood & Co.

Please go ahead. ):

Bram Buring

Excuse me. Hi.

This, well, it's related to the regional expansion, you might not want to answer it at all, but my question was, do any of the neighboring countries that you're looking at, do they support the employer-paid healthcare packages system like you have in Romania? That's the question.

Mihail Marcu

Sorry, I will answer this question again. If in Europe there is something very, very much different in the systems which they try to align as much as they could, they try to make the same motorways, the same distance between the gas stations, they try also to do in different other industries now that they try to align the different related with war industries, but of course I'm not going to far from that.

The whole medical systems, including the one from France and Germany, who are neighbors and they have been the founders of the European Union, they are amazingly different. What we're saying with this IFI is that as long as we cross the border, we need an institution established there for a long time that they know the rules and they can protect us and they can teach us how to make this.

MedLife has a very large expertise. We have expertise in hospitals, clinics, dentistry, laboratories, and so on.

Each of the countries, Bulgaria, Moldova, Serbia, Hungary, and I don't know, Montenegro, they have totally different healthcare systems. What we are saying to you is that is going to be not easy to cross the border.

First, we don't intend to do that in case we succeed and we'll finalize the deal with this IFI that we are discussing with. We are not going to go with one hospital in one country, one lab in one country, and two clinics in another country.

We need two countries where we can grow €50 to €100 million. For MedLife, that is already reaching close to €700 million this year, We don't have the management size and the knowledge to have in each country a clinic or a lab.

We need to test and find together with this IFI two countries, maybe maximum three, where we'll have the expertise to scale up one of our business models. This is a subject which is not for this moment because we have not finalized this with the IFI, and I believe the discussions with them, even if they will agree or will approve such a structure which we are trying to put in place, it will take two more months to discuss the contracts with our lawyer and to make the plans with them where we are going to test and how we are going to test the markets.

This is why I'm saying we are not going to jump there and make acquisition. Don't expect MedLife and this IFI to acquire a company of I don't know, €100 million sales or even €50 million sales.

Expect to make steps like €5 million, €10 million, €15 million max in one country, and then to test it, wait one year, and then see if that model works. What I'm saying is today for us is more important maybe to contemplate the capital increase and to grow in Romania, which we know to do it and we are going to do much faster, then this one which we announces to be very transparent to the shareholders that we are contemplating to do such a structure.

This is not going to be on short, and this is going to be a medium-term investment if is going to happen. ):

Bram Buring

Understood. Sounds prudent.

I was just trying to figure out if the corporate angle of your business is replicable in the neighboring markets. That was my only aim.

Thank you very much for the explanation.

Mihail Marcu

I still want to answer this. I don't believe the corporate business, except if we go to Poland, which is a mature market and MedLife does not aim to reach that market, the corporate market as it is today in Romania is not going to work in any of the neighborhood country for the time being.

):

Bram Buring

Cool. Clear.

Thank you.

Operator

There are no further audio questions. I will now pass the floor to management to accommodate any written questions from the webcast participants.

Dorin Preda

Thank you very much. I will try to answer the questions that we have in the platform, probably group them by subjects, not necessarily take them one by one.

I have a question which is actually referring to the revenues increasing for the pharmacies, and the question was if this increase is mostly linked to the higher client volumes, but also with improved product mix. It is, actually.

There are a few factors here. Actually, we have an influence coming from a new pharmacy that has been opened this year, Pharmalife pharmacy.

Then we have an increase of number of customers, which we see actually in all our facilities, as I said, in all our business lines. There is a change in the market as well, because mainly the biggest network of pharmacy started to produce their own-brand products, and because of that, there is a huge pressure coming from the producers to promote their products in the independent pharmacies, and this is one of the reason you are seeing also this increase year-by-year.

This is also connected with another question that we got, which is referred to other revenue that has been decreased. It's actually the other face of the coin, because if the pharmacies were increasing that much and because the producers were doing so much pressure on the independent pharmacies to grow, the distribution was not that successful.

Then we have interest about the pricing power. Still, we don't have plans to increase power by the end of the year.

Of course, there are discussions that we have regarding this, but unfortunately, still the available funds for spending are not starting to grow yet. We are looking ahead for the inflation.

We are looking ahead because of the exchange rates that has increased during the year, and we'll do all our best to transfer it to our patients, but at least until the end of the year, we don't see this being possible. Then going forward, I see questions regarding the EBITDA, if the EBITDA of 16.1% in Q3 was how much of it was structural, pricing, efficiencies, mature units, and how much it's seasonal.

I would say that the biggest part of it is structural. There are some influences coming from a very good month of August in terms of revenue, but other than that, the majority of it is structural.

Speaking about a possible return to the 20% growth in the past year by adding acquisitions, the question is how important is the pipeline that we have for the M&A, what segments and what regions are we targeting? As you probably already know, we are following very close the market, Romania, but also other markets around us, because, of course, we are in Moldova, we are in Hungary, and we try to understand what is happening in each and every market.

There are a number of directions that we want to develop. Of course that the Sfânta Maria brand needs to go as much as expanding their network in the country, but there are other segments where we already develop on the vertical side.

I would say that we have experience here. We have been, I would say, very good in finding good companies and very good in integrating them, this would be the response that I would have for this question.

I have another question which is related to the increase in revenue for the hospital, which is 12.7. The question is what drove this?

Again, the number of patients, mainly. Then the improvement in average ticket is not that important.

It is something, but not that important. I would say that the biggest part of this growth is coming from increasing number of patients and increasing complexity.

The question regarding the National Health House for the other two hospital I think has been already covered. Then going forward, we decided not to take any questions regarding the capital increase, because it is not on the table as we speak.

I have another questions on monetization of the latest informations like genetics and everything. I think I will touch this question in my ending remarks.

Caius, just few moments to close. I think these are all the questions for today.

Before closing, I'd like to make few remarks. Again, thank you very much, all of you, because you are here today with us for the presentation of the MedLife's results for the first nine months of the year.

I have three remarks, three important remarks that have been mentioned by Flavia before, but I think we need to make a bit of emphasis on that. The first one: the company performed very well in the last quarter, despite the big macroeconomic challenges and despite the big pressure that we are seeing on the household budgets.

In the last nine months, MedLife grew with more than 20%, and this percent was mainly driven by organic growth and mainly driven by treating more patients, and this is something that we are very proud of. This also come together with an increase in profitability and increasing operational efficiency, and then this type of activities looking on how we become more and more profitable is something that we have on our desk every day.

The second remark that we have is that one of maybe one of the biggest moves that we've done this year is that we have started our digital transformation journey with IMed. You all already know that IMed combines medical, genetic, and biometric data to improve patient experience.

It also provides a clear picture of the health of each patient, but also it helps a lot the patients to understand the benefits of the personalized, preventive medicine. More important than that, and I think here I will respond to Caius's question, comparing to the last year, the number of people downloading the application of MedLife and, more than that, the time of them using the application doubled comparing with last year, and I think that we are seeing a new gate opening for patient to access our services.

Traditionally, we're having the clinics that were used to be our main gate for patient, and from the clinics, we're referring patient to other business lines. Then we have the corporate business, which again became the second gate.

It seems that IMed and MedLife app becomes the third gate for getting our patients inside. It comes together with our capacity to sequence eight genetic testings.

It comes together with our capacity to do the microbiome testing, to our capacity to provide pharmacogenetics in Romania. We are the single lab that is doing this here in Romania and not sending tests outside.

Together with that, there is an increasing perception that the patient has that MedLife is doing complicated things, and this is the place for them to be in case they have medical issues. The third and the last one is that, looking ahead, we have these two scenarios that have been discussed already.

We want to still develop our network in Romania, and here we are going to stay alert in acquiring small and medium healthcare facilities, but also wellness and beauty centers, but in the same time, we'll continue to invest in technology, in digitalization, and in personalized, prevention medicine. Looking regionally, as Mihail was saying a bit earlier, we are looking to expand gradually.

We don't want to make big moves, as Mihail was saying a bit earlier. Even if at the beginning we look at the Balkan, the overall scope is to look at the CEE.

Of course that going outside it's motivated by the fact that in the last 30 years, we have succeeded to create a business model that actually is treating the patient in every stage. Even if we speak about prevention, about diagnostic, about treatment, about follow-up or digital experience, it's a model that we can and we want to take to other markets.

Of course that, in order to do so, we are considering the financing options that have been already mentioned here, this would give us the flexibility to act and to take the opportunities in Romania and abroad. Thank you very much for being here tonight and have all of you a very good weekend.

Thank you very much.